ZAC1 target genes and pituitary tumorigenesis

Molecular and Cellular Endocrinology

Volumn 326, Issue 1-2, 2010, Pages 60-65

  Theodoropoulou, Marily ^a   Stalla, Günter K ^a   Spengler, Dietmar ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Biomarker; Pituitary; Somatostatin; Target genes; ZAC1

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENYLATE CYCLASE; ANGIOPEPTIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1C; DUAL SPECIFICITY PHOSPHATASE 2; MESSENGER RNA; OCTREOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P53; PROTEIN P73; TRANSCRIPTION FACTOR ZAC1; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

APOPTOSIS; CANCER INVASION; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE REGULATION; DNA BINDING; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENE TARGETING; GROWTH INHIBITION; HETEROZYGOSITY LOSS; HORMONAL REGULATION; HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; IMMUNOREACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; TRANSCRIPTION INITIATION; UPREGULATION;

ANIMALS; CELL CYCLE PROTEINS; CYCLINS; DNA-BINDING PROTEINS; HUMANS; MICE; NUCLEAR RECEPTOR COACTIVATORS; P300-CBP TRANSCRIPTION FACTORS; PITUITARY GLAND; PITUITARY NEOPLASMS; SOMATOSTATIN; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; ZINC FINGERS;

EID: 77955312398     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.01.033     Document Type: Review

References (52)

1. Abdollahi A. LOT1 (ZAC1/PLAGL1) and its family members: mechanisms and functions. J. Cell. Physiol. 2007, 210:16-25.
2. Abdollahi A., Godwin A.K., Miller P.D., Getts L.A., Schultz D.C., Taguchi T., Testa J.R., Hamilton T.C. Identification of a gene containing zinc-finger motifs based on lost expression in malignantly transformed rat ovarian surface epithelial cells. Cancer Res. 1997, 57:2029-2034.
3. Arima T., Drewell R.A., Arney K.L., Inoue J., Makita Y., Hata A., Oshimura M., Wake N., Surani M.A. A conserved imprinting control region at the HYMAI/ZAC domain is implicated in transient neonatal diabetes mellitus. Hum. Mol. Genet. 2001, 10:1475-1483.
4. Arima T., Kamikihara T., Hayashida T., Kato K., Inoue T., Shirayoshi Y., Oshimura M., Soejima H., Mukai T., Wake N. Zac, Lit1 (Kcnq1Ot1) and P57(Kip2) (Cdkn1C) are in an imprinted gene network that may play a role in Beckwith-Wiedemann syndrome. Nucleic Acids Res. 2005, 33:2650-2660.
5. Barz T., Hoffmann A., Panhuysen M., Spengler D. Peroxisome proliferator-activated receptor gamma is a Zac target gene mediating Zac antiproliferation. Cancer Res. 2006, 66:11975-11982.
6. Basyuk E., Coulon V., Le Digarcher A., Coisy-Quivy M., Moles J.P., Gandarillas A., Journot L. The candidate tumor suppressor gene ZAC is involved in keratinocyte differentiation and its expression is lost in basal cell carcinomas. Mol. Cancer Res. 2005, 3:483-492.
7. Bhayana S., Booth G.L., Asa S.L., Kovacs K., Ezzat S. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J. Clin. Endocr. Metab. 2005, 90:6290-6295.
8. Bilanges B., Varrault A., Basyuk E., Rodriguez C., Mazumdar A., Pantaloni C., Bockaert J., Theillet C., Spengler D., Journot L. Loss of expression of the candidate tumor suppressor gene ZAC in breast cancer cell lines and primary tumors. Oncogene 1999, 18:3979-3988.
9. Bilanges B., Varrault A., Mazumdar A., Pantaloni C., Hoffmann A., Bockaert J., Spengler D., Journot L. Alternative splicing of the imprinted candidate tumor suppressor gene ZAC regulates its antiproliferative and DNA binding activities. Oncogene 2001, 20:1246-1253.
10. Bilodeau S., Roussel-Gervais A., Drouin J. Distinct developmental roles of cell cycle inhibitors p57(Kip2) and p27(Kip1) distinguish pituitary progenitor cell cycle exit from cell cycle reentry of differentiated cells. Mol. Cell. Biol. 2009, 29:1895-1908.
11. Bonofiglio D., Qi H., Gabriele S., Catalano S., Aquila S., Belmonte M., Ando S. Peroxisome proliferator-activated receptor gamma inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21(Cip1/WAF1) gene in a Sp1-dependent. Endocr. Relat. Cancer 2008, 15:545-557.
12. Ciani E., Hoffmann A., Schmidt P., Journot L., Spengler D. Induction of the PAC1-R (PACAP-type I receptor) gene by p53 and Zac. Mol. Brain Res. 1999, 69:290-294.
13. Cvetkovic D., Pisarcik D., Lee C., Hamilton T.C., Abdollahi A. Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer. Gynecol. Oncol. 2004, 95:449-455.
14. Facchetti M., Uberti D., Memo M., Missale C. Nerve growth factor restores p53 function in pituitary tumor cell lines via trkA-mediated activation of phosphatidylinositol 3-kinase. Mol. Endocrinol. 2004, 18:162-172.
15. Gardner R.J., Mackay D.J.G., Mungall A.J., Polychronakos C., Siebert R., Shield J.P.H., Temple I.K., Robinson D.O. An imprinted locus associated with transient neonatal diabetes mellitus. Hum. Mol. Genet. 2000, 9:589-596.
16. Hatada I., Mukai T. Genomic imprinting of P57(Kip2), cyclin-dependent kinase inhibitor, in mouse. Nat. Genet. 1995, 11:204-206.
17. Hatada I., et al. An imprinted gene p57(KIP2) is mutated in Beckwith-Wiedemann syndrome. Nat. Genet. 1996, 14:171-173.
18. Heaney A.P., Fernando M., Melmed S. PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J. Clin. Invest. 2003, 111:1381-1388.
19. Heaney A.P., Fernando M., Yong W.H., Melmed S. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat. Med. 2002, 8:1281-1287.
20. Hoffmann A., Barz T., Spengler D. Multitasking C2H2 zinc fingers link zac DNA binding to coordinated regulation of p300-histone acetyltransferase activity. Mol. Cell. Biol. 2006, 26:5544-5557.
21. Hoffmann A., Ciani E., Boeckardt J., Holsboer F., Journot L., Spengler D. Transcriptional activities of the zinc finger protein Zac are differentially controlled by DNA binding. Mol. Cell. Biol. 2003, 23:988-1003.
22. Hoffmann A., Ciani E., Houssami S., Brabet P., Journot L., Spengler D. Induction of type I PACAP receptor expression by the new zinc finger protein Zac1 and p53. VIP PACAP Relat. Peptides 1998, 865:49-58.
23. Hoffmann A., Spengler D. A new coactivator function for Zac1's C2H2 zinc finger DNA-binding domain in selectively controlling PCAF activity. Mol. Cell. Biol. 2008, 28:6078-6093.
24. Huang S.M., Huang S.P., Wang S.L., Liu P.Y. Importin alpha 1 is involved in the nuclear localization of Zac1 and the induction of p2l (WAF1/CIP1) by Zac1. Biochem. J. 2007, 402:359-366.
25. Huang S.M., Schonthal A.H., Stallcup M.R. Enhancement of p53-dependent gene activation by the transcriptional coactivator Zac1. Oncogene 2001, 20:2134-2143.
26. Huang S.M., Stallcup M.R. Mouse Zac1, a transcriptional coactivator and repressor for nuclear receptors. Mol. Cell. Biol. 2000, 20:1855-1867.
27. Kamiya M., et al. The cell cycle control gene ZAC/PLAGL1 is imprinted-a strong candidate gene for transient neonatal diabetes. Hum. Mol. Genet. 2000, 9:453-460.
28. Koy S., Hauses M., Appelt H., Friedrich K., Schackert H.K., Eckelt U. Loss of expression of ZAC/LOT1 in squamous cell carcinomas of head and neck. Head Neck 2004, 26:338-344.
29. Lehrke M., Lazar M.A. The many faces of PPAR gamma. Cell 2005, 123:993-999.
30. Mackay D.J.G., Coupe A.M., Shield J.P.H., Storr J.N.P., Temple I.K., Robinson D.O. Relaxation of imprinted expression of ZAC and HYMAI in a patient with transient neonatal diabetes mellitus. Hum. Genet. 2002, 110:139-144.
31. Matsuoka S., Thompson J.S., Edwards M.C., Barletta J.M., Grundy P., Kalikin L.M., Harper J.W., Elledge S.J., Feinberg A.P. Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57(KIP2), on chromosome 11p15. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:3026-3030.
32. Murray R.D., Kim K., Ren S.G., Lewis I., Weckbecker G., Bruns C., Melmed S. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J. Clin. Endocr. Metab. 2004, 89:3027-3032.
33. Noh T.W., Jeong H.J., Lee M.K., Kim T.S., Kim S.H., Lee E.J. Predicting recurrence of nonfunctioning pituitary adenomas. J. Clin. Endocr. Metab. 2009, 94:4406-4413.
34. Noviello C., Courjal F., Theillet C. Loss of heterozygosity on the long arm of chromosome 6 in breast cancer: possibly four regions of deletion. Clin. Cancer Res. 1996, 2:1601-1606.
35. Nussdorfer G.G., Malendowicz L.K. Role of VIP, PACAP, and related peptides in the regulation of the hypothalamo-pituitary-adrenal axis. Peptides 1998, 19:1443-1467.
36. Pagotto U., Arzberger T., Ciani E., Lezoualc'h F., Pilon C., Journot L., Spengler D., Stalla G.K. Inhibition of Zac1, a new gene differentially expressed in the anterior pituitary, increases cell proliferation. Endocrinology 1999, 140:987-996.
37. Pagotto U., Arzberger T., Theodoropoulou M., Grubler Y., Pantaloni C., Saeger W., Losa M., Journot L., Stalla G.K., Spengler D. The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Res. 2000, 60:6794-6799.
38. Ptashne M., Gann A. Transcriptional activation by recruitment. Nature 1997, 386:569-577.
39. Rodriguez-Henche N., Jamen F., Leroy C., Bockaert J., Brabet P. Transcription of the mouse PAC1 receptor gene: cell-specific expression and regulation by Zac1. Biochim. Biophys. Acta 2002, 1576:157-162.
40. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G(1)-phase progression. Gene Dev. 1999, 13:1501-1512.
41. Sherr C.J., Roberts J.M. Living with or without cyclins and cyclin-dependent kinases. Gene Dev. 2004, 18:2699-2711.
42. Spengler D., Villalba M., Hoffmann A., Pantaloni C., Houssami S., Bockaert J., Journot L. Regulation of apoptosis and cell cycle arrest by Zac1, a novel zinc finger protein expressed in the pituitary gland and the brain. EMBO J. 1997, 16:2814-2825.
43. Spengler D., Waeber C., Pantaloni C., Holsboer F., Bockaert J., Seeburg P.H., Journot L. Differential signal-transduction by 5 splice variants of the Pacap receptor. Nature 1993, 365:170-175.
44. Temple I.K., Shield J.P.H. Transient neonatal diabetes, a disorder of imprinting. J. Med. Genet. 2002, 39:872-875.
45. Theodoropoulou M., Arzberger T., Gruebler Y., Jaffrain-Rea M.L., Schlegel J., Schaaf L., Petrangeli E., Losa M., Stalla G.K., Pagotto U. Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J. Endocrinol. 2004, 183:385-394.
46. Theodoropoulou M., et al. Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. Int. J. Cancer 2009, 125:2122-2126.
47. Theodoropoulou M., Zhang J., Laupheimer S., Paez-Pereda M., Erneux C., Florio T., Pagotto U., Stalla G.K. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res. 2006, 66:1576-1582.
48. Valente T., Auladell C. Expression pattern of Zac1 mouse gene, a new zinc-finger protein that regulates apoptosis and cellular cycle arrest, in both adult brain and along development. Mech. Dev. 2001, 108:207-211.
49. Valente T., Junyent F., Auladell C. Zac1 is expressed in progenitor/stem cells of the neuroectoderm and mesoderm during embryogenesis: differential phenotype of the Zac1-expressing cells during development. Dev. Dyn. 2005, 233:667-679.
50. Varrault A., Bilanges B., Mackay D.J.G., Basyuk E., Ahr B., Fernandez C., Robinson D.O., Bockaert J., Journot L. Characterization of the methylation-sensitive promoter of the imprinted ZAC gene supports its role in transient neonatal diabetes mellitus. J. Biol. Chem. 2001, 276:18653-18656.
51. Varrault A., Ciani E., Apiou F., Bilanges B., Hoffmann A., Pantaloni C., Bockaert J., Spengler D., Journot L. hZAC encodes a zinc finger protein with antiproliferative properties and maps to a chromosomal region frequently lost in cancer. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:8835-8840.
52. Varrault A., et al. Zac1 regulates an imprinted gene network critically involved in the control of embryonic growth. Dev. Cell 2006, 11:711-722.